HALLE (SAALE), Germany, 02 February 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
HALLE (SAALE), Germany, 09 January 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces that recruitment […]
HALLE (SAALE), Germany, 04 January 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Poster presentation at CTAD, San Diego, 8-10 December 2016 HALLE (SAALE), Germany, 8 December 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing […]
HALLE (SAALE), Germany, 16 November 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced today […]
HALLE (SAALE), Germany, 14 November 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), is scheduled to […]
HALLE (SAALE), Germany, 10 November 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
HALLE (SAALE), Germany, 3 November 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]
Attendance at key conferences in November 2016 HALLE (SAALE), Germany, 27 October 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]